Healthcare / Pharmaceutical RetailersSão Paulo
$4.10
-0.17 (-3.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $282.3M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.0B
P/E
8.4x
↓EV/EBITDA
5.0x
↓ROE
8.4%
↑Gross Margin
32.0%
↓Debt/Equity
1.20
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+17.5%
FCF CAGR
—
FCF margin
-0.4%
FCF / Net income
-0.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.91B · net income $260.3M · FCF $-61.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.91B | $14.91B | $12.64B | $11.20B | $9.19B |
| Net Income | $260.3M | $260.3M | $103.1M | $2.5M | $263.7M |
| EBITDA | $1.21B | $1.21B | $957.5M | $797.9M | $1.11B |
| EPS | 0.42 | 0.42 | 0.22 | 0.00 | 0.58 |
| Gross Margin | 32.0% | 32.0% | 31.8% | 31.6% | 32.1% |
| Operating Margin | 5.7% | 5.7% | 4.5% | 3.6% | 6.9% |
| Net Margin | 1.7% | 1.7% | 0.8% | 0.0% | 2.9% |
| Balance Sheet | |||||
| Debt/Equity | 1.20 | 1.20 | 1.29 | 1.42 | 1.63 |
| Cash Flow | |||||
| Free Cash Flow | $-61.1M | $-61.1M | $282.3M | $368.4M | $-179.1M |
| Returns | |||||
| ROE | 8.4% | 8.4% | 3.8% | 0.1% | 11.3% |
| Valuation | |||||
| P/E | 8.37 | 8.37 | 13.68 | 695.11 | 7.11 |
| EV/EBITDA | 5.03 | 5.03 | 5.34 | 6.35 | 4.99 |
| P/B | 0.83 | 0.83 | 0.65 | 0.66 | 0.80 |
| Growth & Yield | |||||
| Revenue Growth | 17.9% | 17.9% | 12.9% | 21.9% | — |
| EPS Growth | 89.7% | 89.7% | 4367.9% | -99.2% | — |
| Dividend Yield | 12.4% | 12.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-4.5%
EPS terminal req.
$0.36
Spread vs growth
94.2%
5Y implied EPS CAGR
1.0%
EPS terminal req.
$0.44
Spread vs growth
88.6%
10Y implied EPS CAGR
5.4%
EPS terminal req.
$0.71
Spread vs growth
84.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+26.9%
Start / end P/E
16.2x → 9.8x
EPS bridge
0.22 → 0.42
Residual
-35.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.